|Awarded On||February 16, 2022|
|Title||Mechanisms and therapies focused on epigenomic alterations in therapy-resistant prostate cancers|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Kunal Rai|
Prostate cancer related deaths usually occur due to metastatic spread and resistance to various therapies. Historically the median survival for men with advanced therapy-resistant prostate cancer has been less than two years. Whether epigenomic aberrations contribute to evolution of resistant clones in therapy-resistant aggressive prostate cancers is not well understood. In preliminary studies, we profiled various epigenomic elements in therapy-resistant human tumor samples and treatment-naive primary samples to define changes specific to resistant tumors. We found that H3K4me1 (a modification of histone proteins)-marked enhancer states are highly enriched in therapy-resistant samples which ...